The FDA has approved intravenous ocrelizumab for children and adolescents aged 10+ with RRMS, supported by phase 3 OPERETTA 2 data comparing the therapy with fingolimod.
📌 Pediatric MS accounts for ~3-5% of all MS cases globally
📌 Ocrelizumab demonstrated noninferiority in ARR reduction
📌 Dosing every 6 months may offer an additional management consideration for families and clinicians
Our coverage: https://t.co/7WzyZVoWcF
Viewpoint: The updated 2024 McDonald criteria enable MS diagnosis in asymptomatic individuals by incorporating imaging and CSF biomarkers, such as CVS and κ-FLC index, while promoting a single standardized framework. https://t.co/7xElt5zqIp
Open Access:
🧠 #Gepants for kids? Early real-world evidence shows these preventives were generally safe and offered some benefit for youth with #migraine. More research is needed.
Read more: https://t.co/e4YErWaYSp
@aagelfand et al
🚨 OnabotulinumtoxinA (Botox) did not meet efficacy goals for episodic migraine, though safety remained consistent.
🧠 Findings highlight need to explore biological differences between episodic & chronic migraine to refine treatments.
🔗 ➡️ https://t.co/Gq8oiSuwhL
BREAKING NEWS: @Roche have announced their BTK inhibitor, #fenebrutinib, has achieved successful trial results in both relapsing-remitting & primary progressive #MultipleSclerosis. #MS [1/2]
Read more: https://t.co/r9YP533Aw7
It has been a pleasure to host you for #ECTRIMS25.
The whole @cemcat_em team wishes you a safe trip back and a restful weekend. Looking forward to seeing you in #Toronto next year (my second favourite city!)
MAGNIMS–CMSC–NAIMS:"...we provide practical recommendations for imaging strategies & acquisition #MRI protocols for all aspects of #MultipleSclerosis#diagnosis, including sequences for detection of optic nerve lesions and...for assessment of CVS & PRL..." https://t.co/JGoJLFuC8k
Liderat pel Dr. @XMontalban i amb la participació de la Dra. @MarTintore, Dr. @J_SastreGarriga, Dra. @GeoArrambide, Dra. Susana Otero i Dr. Alex Rovira (IDI) de @cemcat_em@vallhebron@VHIR_ es publica a @TheLancetNeuro l'actualització 2024 dels criteris diagnòstics de l'#esclerosimutliple que faciliten el diagnòstic abans dels símptomes i inici de tractament per evitar l'aparició de la discapacitat a mig i llarg termini
Proud to share our new publication in Cephalalgia!
📄 The RESCUE study: Atogepant in migraine patients unresponsive to anti-CGRP mAbs
🎯 18% achieved ≥50% ↓ in headache days
🧠 59% reported improvement
👉 https://t.co/o1qsR4WxH0
#migraine#CGRP#neurology
Author Manuel Comabella discusses Prognostic Factors for Multiple Sclerosis Symptoms in Radiologically Isolated Syndrome with JAMA Neurology Web Editor Cynthia Armand. Listen now: https://t.co/0qB8wc1wJi
La Dra. @ppozorosich, cap del grup de Cefalea i Dolor Neurològic del #VHIR, explica a @LaVanguardia la importància dels gepants per al tractament de la migranya: "els podem recomanar de forma preventiva".
Llegeix-ho 👇
https://t.co/bAcwcmvIhl
RCT: Rizatriptan provided limited benefits for headache-related symptoms but not vertigo in treating vestibular migraine attacks. https://t.co/j6om2hqCMu
Pleased to share the release of the new Migraine Guideline!
A joint effort by the @SISCCefalee and @ihs_official
Two versions are available on @JCephalalgia :
• Summary version: https://t.co/kTUXlYkPNy
• Extended version: https://t.co/P3LQGVHQ00